PURPOSE: In-situ split (ISS) liver resection is a novel method to induce rapid hypertrophy of the contralateral liver lobe in patients at risk for postoperative liver failure due to insufficient liver remnant. So far, no data about oncological long-term survival after ISS liver resection is available. METHODS: We retrospectively analyzed our patients treated with ISS liver resection at the Department of Surgery of the University of Regensburg, the first center worldwide to perform ISS. RESULTS: Between 2007 and 2014, ISS liver resection was performed in 16 patients. Two patients (12.5 %) were lost in early postoperative phase (90 days) and one was lost to follow-up. Thirteen patients with a follow-up period of more than 3 months were included into oncologically focused analyses. Median follow-up was 26.4 months (range 3.2-54.6). Seven patients had suffered from colorectal liver metastases (CRLM) and six from various other liver malignancies (non-CRLM). The ISS procedure had led to a median increase of 86.3 % of the left lateral liver lobe after a median of 9 days (range 4-28 days). Median disease-free survival (DFS) was 14.6 months and median overall survival (OS) was 41.7 months (26.4 months when including 90-days mortality). Three-year survival was calculated with 56.4 and 48.9 % when including perioperative mortality, respectively (CRLM 64.3 % vs. non-CRLM 50 %). CONCLUSION: ISS liver resection can provide long-term survival of selected patients with advanced liver malignancies that otherwise are not eligible for liver resection due to insufficient liver remnant.
PURPOSE: In-situ split (ISS) liver resection is a novel method to induce rapid hypertrophy of the contralateral liver lobe in patients at risk for postoperative liver failure due to insufficient liver remnant. So far, no data about oncological long-term survival after ISS liver resection is available. METHODS: We retrospectively analyzed our patients treated with ISS liver resection at the Department of Surgery of the University of Regensburg, the first center worldwide to perform ISS. RESULTS: Between 2007 and 2014, ISS liver resection was performed in 16 patients. Two patients (12.5 %) were lost in early postoperative phase (90 days) and one was lost to follow-up. Thirteen patients with a follow-up period of more than 3 months were included into oncologically focused analyses. Median follow-up was 26.4 months (range 3.2-54.6). Seven patients had suffered from colorectal liver metastases (CRLM) and six from various other liver malignancies (non-CRLM). The ISS procedure had led to a median increase of 86.3 % of the left lateral liver lobe after a median of 9 days (range 4-28 days). Median disease-free survival (DFS) was 14.6 months and median overall survival (OS) was 41.7 months (26.4 months when including 90-days mortality). Three-year survival was calculated with 56.4 and 48.9 % when including perioperative mortality, respectively (CRLM 64.3 % vs. non-CRLM 50 %). CONCLUSION:ISS liver resection can provide long-term survival of selected patients with advanced liver malignancies that otherwise are not eligible for liver resection due to insufficient liver remnant.
Authors: Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt Journal: Ann Surg Date: 2012-03 Impact factor: 12.969
Authors: Lisette T Hoekstra; Krijn P van Lienden; Ageeth Doets; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik Journal: Ann Surg Date: 2012-11 Impact factor: 12.969
Authors: Alan W Hemming; Alan I Reed; Richard J Howard; Shiro Fujita; Steven N Hochwald; James G Caridi; Irvin F Hawkins; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2003-05 Impact factor: 12.969
Authors: Dennis A Wicherts; Rafael Miller; Robbert J de Haas; Georgia Bitsakou; Eric Vibert; Luc-Antoine Veilhan; Daniel Azoulay; Henri Bismuth; Denis Castaing; René Adam Journal: Ann Surg Date: 2008-12 Impact factor: 12.969
Authors: S Hayashi; Y Baba; K Ueno; M Nakajo; F Kubo; S Ueno; T Aikou; T Komokata; N Nakamura; R Sakata Journal: Acta Radiol Date: 2007-09 Impact factor: 1.990
Authors: Juan Glinka; Victoria Ardiles; Juan Pekolj; Eduardo de Santibañes; Martin de Santibañes Journal: Hepatobiliary Surg Nutr Date: 2020-12 Impact factor: 7.293
Authors: Katharina Joechle; Christian Moser; Petra Ruemmele; Katharina M Schmidt; Jens M Werner; Edward K Geissler; Hans J Schlitt; Sven A Lang Journal: World J Surg Oncol Date: 2017-03-07 Impact factor: 2.754
Authors: Gregor A Stavrou; Marcello Donati; Mohammad H Fard-Aghaie; Martin Zeile; Tessa M Huber; Axel Stang; Karl J Oldhafer Journal: Visc Med Date: 2017-11-30